HS
FATE icon

HighVista Strategies’s Fate Therapeutics FATE Stock Holding History

HighVista Strategies’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-41,194
Closed -$416K – 117
2022
Q4 		$416K Sell
41,194
-70,351
-63% -$1.32M 0.25% 80
2022
Q3 		$2.5M Sell
111,545
-7,233
-6% -$209K 1.43% 26
2022
Q2 		$2.94M Buy
118,778
+54,113
+84% +$1.49M 1.78% 18
2022
Q1 		$2.51M Buy
64,665
+41,584
+180% +$1.61M 1.59% 17
2021
Q4 		$1.35M Buy
23,081
+5,947
+35% +$337K 1.07% 29
2021
Q3 		$1.02M Buy
17,134
+6,006
+54% +$471K 0.67% 51
2021
Q2 		$966K Buy
+11,128
New +$897K 0.69% 23
2020
Q4 		– Sell
-13,807
Closed -$552K – 125
2020
Q3 		$552K Buy
13,807
+1,344
+11% +$46.9K 0.4% 39
2020
Q2 		$428K Buy
+12,463
New +$371K 0.35% 43

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

HighVista Strategies's FATE Position: Q1 2023 in Review

HighVista Strategies sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 41,194 shares — an estimated $416K sold.

HighVista Strategies first reported a position in FATE in Q2 2020 and held it in 9 quarters. The position peaked at $2.94M in Q2 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • HighVista Strategies reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • HighVista Strategies sold 41,194 Fate Therapeutics shares in Q1 2023, an estimated $416K.
  • HighVista Strategies first reported a position in Fate Therapeutics in Q2 2020 and held it in 9 quarters.
  • HighVista Strategies's Fate Therapeutics position peaked at $2.94M in Q2 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.